Accustem Sciences (ACUT) Total Non-Current Liabilities (2022 - 2026)
Accustem Sciences (ACUT) posted quarterly Total Non-Current Liabilities of $5.4 million for Q1 2026, up 51.45% year-over-year from $3.5 million in Q1 2025, and up 12.69% quarter-over-quarter from $4.8 million in Q4 2025.
Accustem Sciences (ACUT) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Total Non-Current Liabilities for 5 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 51.45% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (up 51.45% YoY), while the FY2025 annual figure was $4.8 million, up 44.69% from the prior year.
- Total Non-Current Liabilities climbed to $5.4 million in Q1 2026 per ACUT's latest filing, from $4.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.4 million in Q1 2026 and bottomed at $1.0 million in Q4 2022.
- Historically, Total Non-Current Liabilities has averaged $2.8 million across 5 years, with a median of $3.0 million in 2024.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities decreased 8.62% — and 2025, when it surged 247.53%.
- Accustem Sciences' Total Non-Current Liabilities stood at $1.0 million in 2022, then soared by 108.59% to $2.1 million in 2023, then soared by 55.41% to $3.3 million in 2024, then surged by 44.69% to $4.8 million in 2025, then advanced by 12.69% to $5.4 million in 2026.
- Business Quant data shows ACUT's Total Non-Current Liabilities at $5.4 million in Q1 2026, $4.8 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 9.32 Bn |
| 10 | Accustem Sciences | 2.60 Mn | 2.59 Mn | - | 5.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.36 Mn |
| Dec 31, 2025 | 4.75 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | 4.13 Mn |
| Mar 31, 2025 | 3.54 Mn |
| Dec 31, 2024 | 3.28 Mn |
| Sep 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | 2.11 Mn |
| Sep 30, 2023 | 1.13 Mn |
| Jun 30, 2023 | 1.67 Mn |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 1.01 Mn |